Objective To study the effects of Fluvastatin on the expression of intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells (HUVECs) induced by C-reactive protein (CRP). MethodsThe HUVECs were primary cultured. HUVECs from third to sixth generations were stimulated with different concentrations CRP and at different times. Then the cells were treated with Fluvastatin in different concentration of 10-7,10-6 and 10-5mol/L. The content of ICAM-1 protein was detected with ELISA, the mRNA expression of ICAM-1 was evaluated by RT-PCR. Results In the control group, HUVECs produce ICAM-1 protein and mRNA in low concentrations. In CRP group, the content of ICAM-1 protein was increased significantly (P

Objective To investigate the assessing value of C-reactive protein to serum albumin ratio(CRP/Alb)and pan-im-mune-inflammation value(PIV)in the prognosis of advanced non-small cell lung cancer(NSCLC)before receiving first-line PD-1/PD-L1 inhibitors combined with chemotherapy.Methods The clinical data of 85 patients diagnosed with advanced NSCLC in the Affili-ated Hospital of Xuzhou Medical University from November 2018 to December 2021 who received first-line treatment with PD-1/PD-L1 inhibitors combined with chemotherapy regimens were retrospectively analyzed.The receiver operator characteristic curve(ROC curve)was used to determine the optimal cut-off value of CRP/Alb and PIV,and univariate and multivariate analysis were performed on the COX proportional risk regression model.Results In this study,a total of 85 patients were included,and the optimal cut-off value of CRP/Alb was 0.38,and the difference between the advanced NSCLC patients in the high and low CRP/Alb groups in the history of smok-ing and hypertension was statistically significant(P＜0.05);the optimal cut-off value of PIV was 666.77,and the difference in ECOG-PS scores between the advanced NSCLC patients in the high and low PIV groups was statistically significant(P＜0.05).The dis-ease control rate(DCR)and progression-free survival(PFS)of patients in the high CRP/Alb group and the high PIV group were lower than those in low CRP/Alb and low PIV groups,and the difference was statistically significant(P＜0.05).Univariate and multivariate COX regression analysis showed that high CRP/Alb and high PIV were predictors of poor prognosis of PFS in patients with advanced NSCLC in the first-line treatment of PD-1/PD-L1 inhibitors and chemotherapy regimens.Conclusion High CRP/Alb and high PIV are associated with poorer PFS in patients with advanced NSCLC,and may be potentially valuable prognostic factors for patients with ad-vanced NSCLC treated with first-line immunotherapy combined with chemotherapy.